Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Creo Medical Group's (LON: CREO) shares are down on Friday following the announcement that it has opened its United States headquarters at the Summit, Danbury, Connecticut, USA.
The AIM-listed medical device firm said the space is designed to support Creo's global growth and focus in the key United States market.
The new headquarters has a learning centre and a fully equipped laboratory for clinical development and training purposes.
Craig Gulliford, CEO of Creo, said: “We are delighted and proud to have opened our first United States facility, illustrating our commitment to growth and our focus on the key United States Market.
“These new premises will provide an excellent working environment for our United States team and a platform to attract further talent in this key region of the United States market.”
Despite the upbeat announcement, Creo's share price is down 2.96% on Friday at 180.5p.
Creo Medical shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Creo Medical shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .